toceranib toceranib toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. together with masitinib (kinavet (us)/masivet (eu/row) by ab science), toceranib is the only dog-specific anti-cancer drug approved by the u.s. food and drug administration (fda). it is sold under the brand name palladia as its phosphate salt, toceranib phosphate (inn) by pfizer. it was developed by sugen as su11654, a sister compound to sunitinib, which was later approved for human therapies. toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect. toceranibclinical datatrade namespalladiaahfs/drugs.comveterinary uselicense data us dailymed: toceranib routes ofadministrationby mouthdrug classantineoplastic agentatcvet codeql01ex90 (who) legal statuslegal status ca: ℞-only us: ℞-only pharmacokinetic databioavailability77%protein binding91%-93%elimination half-life16 hidentifiers iupac name 5--2,4-dimethyl-n--1h-pyrrole-3-carboxamide cas number356068-94-5as salt: 874819-74-6pubchem cid5329106as salt: 16034840chemspider4486268as salt: 13163443unii59l7y0530cas salt: 24f9pf7j3rkeggd08503as salt: d08544chemblchembl13608as salt: chembl2103833pdb ligandbwc (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid50189076 chemical and physical dataformulac22h25fn4o2molar mass396.466 g·mol−13d model (jsmol)interactive image smiles fc1ccc2c(c1)/c(c(=o)n2)=c/c4c(c(c(=o)nccn3cccc3)c(4)c)c inchi inchi=1s/c22h25fn4o2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25h,3-4,7-10h2,1-2h3,(h,24,29)(h,26,28)/b17-12-key:srsgvkwwvxwsjt-atvhpveesa-n